Table 2 Prevalence of transmitted drug resistance in the total sample and in subpopulationsa
Drug classb | Total | Gender | Mode of transmission | Country of origin | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Male | Female | Diverse/N. r.c,d | MSMe | HETf | PWIDg | Other/N. r.c,d | Germany | Other | N. r.d | ||||
N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |||
NRTI | 194 (4.3) | 159 (4.2) | 34 (4.4) | 1 (12.5) | 103 (4.3) | 43 (4.6) | 6 (2.8) | 42 (4.3) | 109 (4.1) | 73 (4.9) | 12 (2.9) | ||
NNRTI | 420 (9.2) | 327 (8.7) | 92 (11.9) | 1 (12.5) | 198 (8.2) | 111 (11.8) | 19 (8.9) | 92 (9.3) | 220 (8.3) | 162 (10.8) | 38 (9.2) | ||
PI | 149 (3.3) | 126 (3.3) | 22 (2.9) | 1 (12.5) | 88 (3.6) | 21 (2.2) | 4 (1.9) | 36 (3.6) | 91 (3.4) | 45 (3.0) | 13 (3.2) | ||
INI | 42 (1.4) | 39 (1.5) | 3 (0.6) | 0 (0.0) | 22 (1.3) | 12 (1.9) | 0 (0.0) | 8 (1.2) | 25 (1.4) | 16 (1.6) | 1 (0.4) | ||
NRTI + NNRTI | 53 (1.2) | 36 (1.0) | 17 (2.2) | 0 (0.0) | 16 (0.7) | 21 (2.2) | 5 (2.3) | 11 (1.1) | 24 (0.9) | 25 (1.7) | 4 (< 0.1) | ||
NRTI + PI | 8 (0.2) | 5 (0.1) | 3 (0.4) | 0 (0.0) | 3 (0.1) | 3 (0.3) | 1 (0.5) | 1 (0.1) | 3 (0.1) | 5 (0.3) | 0 (0.0) | ||
NRTI + INI | 3 (< 0.1) | 3 (0.1) | 0 (0.0) | 0 (0.0) | 2 (0.1) | 0 (0.0) | 0 (0.0) | 1 (0.2) | 2 (0.1) | 1 (< 0.1) | 0 (0.0) | ||
NNRTI + PI | 26 (0.6) | 20 (0.5) | 5 (0.6) | 1 (12.5) | 17 (0.7) | 5 (0.5) | 1 (0.5) | 3 (0.3) | 16 (0.6) | 10 (0.7) | 0 (0.0) | ||
NNRTI + INI | 2 (< 0.1) | 2 (< 0.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (0.3) | 0 (0.0) | 1 (< 0.1) | 1 (0.4) | ||
PI + INI | 1 (< 0.1) | 1 (< 0.1) | 0 (0.0) | 0 (0.0) | 1 (< 0.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (< 0.1) | 0 (0.0) | ||
NRTI + NNRTI + PI | 4 (< 0.1) | 3 (< 0.1) | 1 (0.1) | 0 (0.0) | 2 (< 0.1) | 1 (0.1) | 1 (0.5) | 0 (0.0) | 2 (< 0.1) | 2 (0.1) | 0 (0.0) | ||